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Pharmacokinetics of Pirmenol Enantiomers
and Pharmacodynamics of Pirmenol
Racemate in Patients with Premature
Ventricular Contractions
Nancy Janiczek, PhD, David E. Smith, PhD, Tsun Chang, MS, Allen J. Sedman, MD, PhD,
and Kathleen A. Stringer, PharmD
The pharmacokinetics and pharmacodynamics of pirmenol were investigated in 12
patients with premature ventricular contractions (PVCs) after oral administration of
racemic pirmenol, 100mg and 200 mg every 12 hours. Holter monitoring was performed
and serial blood samples were collected after the seventh doses. Plasma concentrations
of pirmenol enantiomer were determined using a stereospecific liquid chromatographic
assay. Clearance of total (-)-pirmenol was 20% higher than that of total (+)-pirmenol,
and the difference in unbound clearance was 45% between enantiomers. Totalpirmenol
showed a smaller difference because of stereoselective protein binding, with 25% (100-
mg dose) or 27% (200-mg dose) higher fraction unbound for (+)-pirmenol than for
(-)-pirmenol. Distribution volume was similar for both enantiomers. Dose-dependent
clearance was observed for unbound pirinenol enantiomers, as both enantioniers
showed 20% lower unbound clearance at the higher dose. Antiarrhythmic effect (%
reduction in PVCs from baseline) was correlated with plasma concentrations ofpirmenol
using a sigmoid maximum drug effect model, and patients showed a large variability
in their antiarrhythmic response to plasma concentrations of pirmenol. The median
value for minimum effective plasma concentration of racemic pirmenol was 1.5 ug/mL.
P irmenol is a chiral compound that is being inves-
tigated as an antiarrhythmic agent in the racemic
form. Pharrnacokinetics and pharmacodynamics of
pirmenol have been studied after its administration
as a racemic mixture. Analytical methods used for
these studies quantified pirmenol as a racemate with-
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out distinguishing between enantiomers. Studies in
healthy individuals and patients with premature
ventricular contractions (PVCs) demonstrated that
pirmenol is well absorbed, with a bioavailability of
85%.1_3 Pirmenol is extensively metabolized, as 20%
to 30% of an administered dose is excreted un-
changed in urine.7 Because unbound renal clear-
ance exceeds glomerular filtration rate, however, the
renal clearance of pirmenol also includes a secretory
process. Pirmenol is 80% to 90% bound to human
plasma proteins at therapeutic plasma concentra-
tions, and the extent of protein binding of pirmenol
is highly correlated with cr1-acid glycoprotein con-
centration in human plasma. Based on substantial
metabolism, secretory renal clearance component,
and extensive plasma protein binding of pirmenol,
possibilities exist for stereoselective pharmacokinet-
ics after administration of racemic drug. In this
study, pharmacokinetic differences between enanti-
omers were evaluated in patients with PVCs after
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repeated oral administration of racemic pirmenol at
two different doses. In addition, the effect of racemic
pirmenol on suppression of PVCs was investigated.
Because individual enantiomers of pirmenol are not
yet approved for administration to humans, only the
racemate could be studied.
PATIENTS AND METHODS
Patients
Twelve patients with PVCs participated in this mul-
tiple-, rising-dose study of pirrnenol. Patients were
included if a 24-hour baseline Holter monitor (Del
Mar Avionics, Irvine, CA) demonstrated at least 720
ectopic beats per 24 hours and if a repeat 24-hour
baseline reading showed a PVC frequency that was
40% to 160% of the initial reading. All patients pre-
viously receiving antiarrhythmic therapy, including
-adrenergic blockers and calcium channel blockers,
were withdrawn from these medications before base-
line Holter monitoring. Concurrent medications
taken during the study were limited to drugs that do
not interfere with drug metabolism and were re-
quired to be taken at least 2 hours before or 4 hours
after pirmenol on the days of blood sampling. Age
of patients ranged from 26 to 79 years, and weight
ranged from 66.4 kg to 96.4 kg. There were nine men
and three women in the study, and two of the pa-
tients were smokers. The protocol and consent form
were approved by the Institutional Review Board of
the Millard Fillmore Hospital (Buffalo, NY). The
study was conducted at the Clinical Pharmacokinet-
ics Laboratory of the Millard Fillmore Hospital. Writ-
ten informed consent was obtained from each pa-
tient.
Study Design
Racemic pirmenol was administered orally at 100 mg
or 200 mg every 12 hours with a 3-day washout pe-
riod between treatments. The 100-mg regimen was
administered on days 1 to 4, and the 200-mg regimen
was administered on days 8 to 11 of the study; a total
of seven doses were given at each dose level. Blood
samples were collected before the morning dose for
blank plasma on day 1 and for trough plasma concen-
tration determinations on days 3 and 10. Holter mon-
itoring was performed and serial blood samples were
collected after the seventh dose (days 4 and 11).
Blood samples (5 mL) were obtained from an in-
dwelling intravenous catheter into evacuated collec-
tion tubes containing heparin before administration
and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, and 48
hours after dose. Plasma was harvested and stored
frozen at -20#{176}Cuntil analysis.
Electrocardiograms were obtained 2 hours after the
morning dose on days 1, 3, 8, and 10. Holter monitor
(24-hour) readings were obtained immediately after
the morning dose on days 3,4, 10, and 11. Additional
24-hour Holter monitor readings were obtained on
days 5 and 12. Clinical laboratory measurements (he-
matology, clinical chemistry, and urinalysis) were
taken on days I and 13, and vital signs were mea-
sured on days 1, 8, and 13.
Plasma Assay
Plasma concentrations of pirmenol enantiomer were
determined using a stereospecific liquid chromato-
graphic assay,8 which was modified for the analysis
of human plasma to eliminate an interfering peak
in the chromatogram. Briefly, racemic pirmenol and
internal standard ((+)-propranolol) were isolated
from human plasma by a three-step extraction proce-
dure using toluene, pH 4.5 citrate-phosphate buffer,
and hexane, in that order. Pirmenol enantiomers and
internal standard were separated using a cellulose-
bonded chiral analytical column (Chiralcel OJ;
Daicel, Tokyo, Japan) and mobile phase consisting
of hexane:isopropanol:diethylamine (98.9:1.0:0.1),
with ultraviolet detection at 262 nm. Linear calibra-
tion curves were obtained in the concentration range
of 0.0203 sg/mL to 5.00 j.tg/mL for each enantiomer.
Validation of the method in dog plasma using nine
replicate sets of calibration standards and quality
controls resulted in a precision of 7.1% or less and a
bias of ±2.2% for both enantiomers. Assay validation
was repeated in human plasma (n = 4), and precision
and bias results were 13.4% or less and ±3.3%, re-
spectively, for (+)-pirmenol, and 14.7% or less and
± 6.0%, respectively, for (-)-pirmenol.
Protein Binding
Unbound concentrations were determined in each
study sample using equilibrium dialysis. Plasma
containing pirmenol (0.75 mL) was dialyzed against
an equal volume of isotonic pH 7.4 phosphate buffer
in a 37#{176}Cshaking water bath for 16 hours (equilibra-
tion was reached, as indicated by preliminary experi-
ments). Plasma and buffer were placed quantitatively
in and removed from dialysis cells using 1.0-mL dis-
posable syringes. Samples were assayed for concen-
trations of pirmenol enantiomer using the liquid
chromatographic method described previously.
Bound concentrations were corrected for volume
shift9 using the following equations:
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Cb’ = Cp’ - Cf’
Gb” = Cb’ (Yi
\Vp
where Cp’ is the concentration of pirmenol in plasma
after dialysis; Cf’ is the concentration of pirmenol in
buffer after dialysis (unbound or free concentration);
Cb’ is the concentration of pirmenol bound in plasma
after dialysis; Cb” is the concentration of pirmenol
bound in plasma after dialysis, corrected for volume
shift; Vp’ is the volume of plasma after dialysis; and
Vp is the volume of plasma before dialysis.
Linear or nonlinear binding was assessed from a
plot of Cb” as a function of Cf’. For nonlinear binding,
a single Langmuir equation best described the Cb”-
versus-Cf1 data:
Gb” - P(1) . Cf’
- P(2) + Cf’
where P(1) and P(2) are capacity and dissociation
constants, respectively. Nonlinear regression was
performed using the program MINSQ II (Version
1.02, MicroMath Scientific Software, Salt Lake City,
UT) and a weighting factor of unity. Goodness of fit
criteria included standard deviation of the parameter
estimates, coefficient of determination (r2), and vi-
sual inspection of the residuals. Because equation 3
describes bound concentration as a function of un-
bound (free) concentration, total concentration be-
fore dialysis (Cp, the sum of bound [Cb] and un-
bound [Cfl concentrations before dialysis) can be ex-
pressed as
Cp = ______ + Cf
Rearrangement of equation 4 results in quadratic
equation 5, which is solved for unbound concentra-
tion (Cf) using the total concentration in the original
plasma sample (Cp) and estimates of P(1) and P(2):
Cf 2 + (P(1) + P(2) - Cp) Cf- Cp . P(2) =0 (5)




(1) compartmental methods. Maximum plasma concentra-
lion (C; 1ug/mL) and time to reach (tm; hours)
were determined from visual inspection of the plasma
(2) concentration-time data. Half-life (t112; hours) was cal-
culated as 0.693/Xe, where X (hr) was determined as
the negative slope of the log-linear terminal phase of
the plasma concentration-time profile. Area under the
plasma concentration-time curve from 0 to 12 hours
(AUC0.12; ,g hr/mL) and area under the first moment
curve (AUMC0_12; j.tg . hr2/mL) were calculated using a
combination of the linear and log trapezoidal rules.
Mean residence lime (MRT; hours) was determined by
dividing the sum of AUMCO.12 and TAUCT by
AUCO_12, where T represents the administration inter-
val (12 hours) and T’ AUCTO. is the AUMC from T
extrapolated to infinity.#{176} Apparent plasma clearance
(Cl/F; mL/rnin) was calculated as Dose/AUC12, and
apparent volume of distribution (Vd/F; L) as Cl/F#{247}k.
(3) The time-averaged f was estimated as AUC0_12 of un-
bound pirmenol divided by AUCO_12 of total pirrnenol.
Statistical differences among the four treatments (100-
mg dose for (+)- and (-)-pirmenol and 200-mg dose
for (+)- and (-)-pirmenol) were evaluated using analy-
sis of variance, and a P value of 0.05 was considered
significant. Multiple treatment comparisons were eval-
uated using Tukey’s test. C,, and AUCO12 values were
normalized to a 100-mg dose (NC,, [pg/mL1 and
NAUCO_12 [tg hr/mL]) for statistical comparison of pa-
rameters at different doses.
Pharmacodynamic Analysis
Effect - concentration profiles for racemic pirmenol
during the 12-hour administration interval after the
final 100-mg and 200-mg doses were combined and
fitted to a sigmoid Em, equation:
#{149}(-‘S
ma
- EC5OS + CS (8)
where E is the percent reduction in PVCs from base-
line; Emax is the maximum drug effect; C is the average
plasma pirmenol concentration (.tg/mL); EC50 is the
plasma concentration at 50% of Em, (j.tg/mL); and S
is a constant that reflects the sigmoid shape of the
effect-concentration curve. Effect data were aver-
aged over 4-hour intervals as PVC frequency was
highly variable. Corresponding average plasma con-
centrations of pirmenol were calculated as AUC0.4,
(7) AUC4_8, and AUC8_I2, each divided by the time inter-
val (4 hours). Baseline PVCs were determined as the
prestudy average number of PVCs per hour from 8:00
AM to 8:00 PM, representing the time of day during
which PVCs after the final dose of pirmenol were
analyzed. Both initial and repeat Holter monitor read-
(6)
Similarly, for linear binding, f was calculated us-
ing the following equation:
- Cf’
- Cf’ + Gb”
Pharmacokinetic Analysis
Pharrnacokinetic parameters were calculated at steady
state for each enantiomer (days 4 and 11) using non-
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ings (during subject selection) were included in the
calculation of baseline PVCs. Emax was held constant
at 100%, and EC50 and S values were estimated using
nonlinear least-squares regression with the program
MINSQ II and a weighting factor of unity. Effective
therapeutic concentration, expressed as the concen-
tration at which PVC reduction was 90% (EC90;
was calculated using the parameter estimates
and a rearrangement of equation 8, such that EC90 =
EC50/0.11 11/S
RESULTS
Pharmacokinetics of Enantiomers of Pirmenol
Pharmacokinetic parameters for total and unbound
enantiomers of pirmenol and results of statistical
comparisons among enantiomers and between doses
are given in Table I. Total plasma concentrations of
(+)-pirmenol exceeded those of total (-)-pirmenol
(Figure 1), with NAUCO_12 values that were 13% and
19% higher for total (+)-pirmenol after the 100-mg
and 200-mg doses, respectively. Differences in total
NAUCO_12 were statistically significant. Total Cmax
and tmax of pirmenol were not significantly different
(NS) for (+)- and (-)-pirmenol. Cl/F of total (+)-pir-
menol was 15% lower (significant) at 100 mg and
18% lower (significant) at 200 mg compared with
total (-)-pirmenol, whereas Vd/F based on total drug
was nearly identical for both enantiomers. As a re-
sult, t2 was 13% (significant) and 17% (significant)
longer for total (+)-pirmenol than for total (-)-pir-
menol after 100-mg and 200-mg doses, respectively.
MRT was approximately 20% longer (significant) for
(+)-pirmenol at both doses. No statistically signifi-
cant differences were observed between doses for the
pharmacokinetic parameters of total pirmenol en-
antiomers.
Plasma concentrations of unbound (+)-pirmenol
also exceeded those of unbound (-)-pirmenol (Fig-
ure 2). Unbound pirmenol showed 33% (NS) and
35% (significant) higher Cmax values for (+)-pirmenol
at 100 mg and 200 mg, respectively, than (-)-pir-
menol, with similar tmax values for both enantiomers.
Differences in AUCO_12 between unbound enantiom-
ers were even greater than for total drug, with 44%
(significant) and 53% (significant) higher AUC0_12
values for unbound (+)-pirmenol than for unbound
(-)-pirmenol after 100-mg and 200-mg doses, re-
spectively. Apparent plasma clearance of unbound
(-)-pirmenol (Cl/F) was 42% greater (significant)
at 100 mg and 49% greater (significant) at 200 mg
compared with (+)-pirmenol. Unbound volumes of
distribution (Vd/F) differed by 10% to 20% (NS)
between enantiomers, with Vd/F greater for (-)-pir-
menol than for (+)-pirmenol. The t2 values were
31% (significant) and 22% (significant) longer for
unbound (+)-pirmenol at 100 mg and 200 mg, respec-
tively. MRT was approximately 20% longer (NS) for
(+)-pirmenol at both doses. Protein binding in
plasma was stereoselective, as observed by the 25%
(significant; 100 mg) and 27% (significant; 200 mg)
higher f for (+)-pirmenol than for (-)-pirmenol.
Pharmacodynamics of Racemic Pirmenol
Individual effect-concentration profiles are shown
for three patients in Figure 3. These profiles repre-
sent three different general appearances that were
observed: 1) effect data distributed over a wide range
of effect (patient no. 4); 2) effect data mostly at or
near full suppression of PVCs (patient no. 10); and
3) effect-concentration data displaying possible hys-
teresis (patient no. 2). Of the 12 patients, 5 showed
a wide range of effect, 5 had extensive suppression
of PVCs (>80%) for the administration interval, and
2 showed possible hysteresis. Two of the 12 patients
showed 100% suppression of PVCs during the entire
administration interval. Therefore, fitting of the ef-
fect-concentration data was performed only for the
remaining 10 patients.
Pharmacodynamic parameter estimates are listed
in Tables II and III for total and unbound pirmenol,
respectively. Estimates of EC50 ranged from 0.080
jig/mL to 1.58 g/mL (20-fold) with a mean value of
0.73 tg/mL, and S values ranged from approximately
1 to 5 (mean 3.01) for total racemic pirmenol. EC90
values for total racemic pirmenol ranged from 0.40
tg/mL to 11.3 tg/mL (mean, 2.29 ug/mL). Because
patient no. 12 showed an unusually high EC90 value,
a mean EC90 was also calculated in the absence of
this patient (1.29 jig/mL). For unbound racemic pir-
menol, EC50 estimates ranged from 0.0041 .tg/mL to
0.25 g/mL (61-fold) with a mean value of 0.12
pg/mL, and S values ranged from approximately 1
to 4 (mean, 2.55). EC90 values for unbound racemic
pirmenol ranged from 0.045 g/mL to 1.62 tg/mL
(mean, 0.38 g/mL) and from 0.045 tg/mL to 0.57
tg/mL (mean, 0.25 ig/mL) without patient no. 12.
DISCUSSION
Small but significant differences were observed be-
tween plasma concentrations of pirmenol enantiom-
ers based on total drug. Cl/F was significantly lower
and t,2 was significantly longer for (+)-pirmenol
than for (-)-pirmenol, although these differences
were 21% or less. When these pharmacokinetic pa-
rameters were based on unbound drug, however, a
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Figure 1. Mean (±SE) plasma concentrations of total and unbound
pirmenol enantiomers after repeated oral administration of 100
mg of racemic pirmenol every 12 hours on days 1 through 4 to
patients with PVCs (n = 12). Data are from the day 4 dose.
served (49%). The more rapidly cleared unbound
(-)-pirmenol also had a lower f in plasma. Conse-
quently, stereoselective protein binding was in the
opposite direction to that of intrinsic clearance, thus
minimizing differences in the Cl/F of pirmenol based
on total drug.
Disopyramide, which has a chemical structure simi-
lar to pirmenol, showed a lack of stereoselecivity in
total drug clearance with a significant difference be-
tween the enantiomers in clearance of unbound
drug.1114 Like pirmenol, the enantiomer with higher
unbound clearance (i.e., S(+)-disopyramide) was also
the enantiomer with lower f in plasma. Stereoselective
plasma clearances have been reported for other antiar-
rhythmic agents such as tocainide1517 (higher clear-
ance for R(-)-enantiomer), mexiletine18 (higher clear-
ance for R(-)-enantiomer), flecainide19 (higher clear-
ance for S(+)-enantiomer in poor metabolizers),
encainide2#{176} (higher clearance for (-)-enantiomer in ex-
tensive metabolizers), propafenone21’22 (higher clear-
ance for S(+)-enantiomer), propranolol2326 (higher
clearance for R(+)-enantiomer), verapamil2729 (higher
clearance for S(-)-enantiomer), and nitrendipine30’31
(higher clearance for R(+)-enantiomer).
Higher clearance of (-)-pirmenol is not likely a
result of stereoselective first-pass metabolism in the
liver as pirmenol is not a high extraction ratio drug.
Nonrenal blood clearance of pirmenol was reported
as 100 mL/min in patients with PVCs.1 When this
Figure 2. Mean (±SE) plasma concentrations of total and unbound
pirmenol enantiomers after repeated oral administration of 200
mg of racemic pirrnenol every 12 hours on days 8 through 11 to
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profiles for total and unbound
pirmenol in representative pa-
tients after the combined final
100-mg and 200-mg doses of re-
peated oral administration of ra-
cemicpirmenol every 12 hours to
patients with PVCs. Data in pa-
rentheses were not used in de-
termining the computer-fitted
parameters.
value is compared with an average value of 1,350
mL/min for liver blood flow, pirmenol is estimated
to have a low hepatic extraction (<10%). In addition,
the apparent t112 of (+)-pirmenol was significantly
longer than (-)-pirmenol, which is more suggestive
of an enantiomer difference in systemic elimination.
Difference in intrinsic (unbound) clearance be-
tween (+)- and (-)-pirmenol may be a result of ste-
reoselective metabolic clearance, renal clearance, or
both. (-)-Pirmenol may be preferentially metabo-
lized compared with (+)-pirmenol. Also, if the secre-
tion component of renal excretion is stereoselective,
(-)-pirmenol may be excreted more efficiently than
(+)-pirmenol. Although metabolic clearance is the
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TABLE II
Pharmacodynamic Parameters for Total Pirmenol in Patients with Premature Ventricular Contractions after the Final
Dose of Repeated Oral Administration of Racemic Pirmenol at 100 mg and 200 mg Every 12 Hours
Baseline EC00 $
Patient PVCS/hr Estimate SD Estimate r2 EC90SD
it 4 - - - - - <1.06
2 915 0.63 0.06 2.99 0.65 0.906 1.31
3 681 0.65 0.04 5.32 1.34 0.923 0.98
4 976 1.58 0.05 5.19 0.87 0.963 2.41
5 125 0.90 0.12 3.10 1.41 0.725 1.83
6 120 0.81 0.01 3.31 0.17 0.997 1.57
7 301 0.080 0.048 1.36 0.34 0.878 0.40
8 917 0.35 0.09 2.59 0.95 0.842 0.82
9t 74 - - - - - <1.42
10 837 0.21 0.07 2.38 0.71 0.807 0.53
11 237 0.79 0.09 2.82 0.98 0.842 1.72
12 536 1.28 0.26 1.01 0.32 0.754 11.3
Mean 0.73 3.01 2.29




Based on an 8 .At to 8 PM time interval (12 hours) whereas baseline PVCs4ir for entry into the study were determined
during an 8 to 8 time interval (24 hours).
t Subjects 1 and 9 showed 100% Pvc suppression during the entire administration interval; estimated ECw values were
not included in calculation of mean values.
pvc, premature ventricular contraction; ECw, plasma drug concentration at 50% of E,,,, (pg/mL); EC0), plasma drug
concentration at 90% of E, (ig/mL).
major route of elimination for pirmenol, it can not
be assumed that the stereoselective difference in in-
trinsic clearance is only due to metabolism. As renal
clearance was not determined in this study, how-
ever, the relative contribution of metabolism and re-
nal excretion to the total clearance of each enanti-
omer is not known.
Pharmacokinetics of pirmenol appear to be dose
proportional from 100 mg to 200 mg when total pir-
menol is measured. However, dose-dependent clear-
ance was observed for unbound pirmenol, with a
20% reduction in apparent plasma clearance at the
higher dose for both enantiomers. This would sug-
gest that metabolism or final clearance of pirmenol
may be saturable; however, unbound clearance
should be studied over a wider range of doses to
evaluate dose dependence. The dose proportionality
observed for total pirmenol may be a result of similar
but opposite effects on the f and intrinsic (unbound)
clearance. Average f was approximately 25% higher
at the higher dose for both enantiomers (Table I).
Higher f at the 200-mg dose compared with the 100-
mg dose probably contributed to higher concentra-
tions of unbound drug at the higher dose than would
have been observed if binding was linear. These un-
bound drug concentrations may have resulted in a
reduced intrinsic (unbound) clearance of pirmenol
at the higher dose; thus, the apparent plasma clear-
ance of the enantiomers of total pirmenol appeared
independent of dose.
The time course of drug effect is shown in Figure
4; suppression of PVCs is generally highest in the
first 4-hour interval after administration, followed
by a gradual return of PVCs as drug concentrations
decrease. Two patients (nos. 2 and 6) showed an
apparent hysteresis in their effect-concentration
profile, suggesting an equilibration delay in drug re-
sponse. Because only 2 of the 12 patients displayed
this effect, the apparent preequilibration data were
omitted from pharmacodynamic modeling for these
patients.
Pharmacodynamic analysis of racemic pirmenol
showed good correlation between antiarrhythmic ef-
fect and plasma concentrations of pirmenol, with r2
values ranging from 0.725 to 0.997 for total pirmenol
and from 0.72 7 to 0.999 for unbound pirmenol (Ta-
JANICZEK ET AL
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TABLE Ill
Pharmacodynamic Parameters for Unbound Pirmenol in Patients with Premature Ventricular Contractions after the
Final Dose of Repeated Oral Administration of Racemic Pirmenol at 100 mg and 200 mg Every 12 Hours
Baseline EC $
Patient PVCs/hr Estimate SD Estimate SD EC90
it 4 - - - - - <0.16
2 915 0.077 0.010 2.52 0.63 0.879 0.18
3 681 0.12 0.01 4.42 1.12 0.923 0.20
4 976 0.25 0.01 4.12 0.66 0.969 0.43
5 125 0.13 0.02 2.64 1.22 0.727 0.30
6 120 0.14 0.002 2.77 0.10 0.999 0.31
7 301 0.0041 0.0036 0.92 0.23 0.891 0.045
8 917 0.047 0.014 2.56 1.09 0.802 0.11
9t 74 - - - - - <0.21
10 837 0.031 0.010 2.21 0.65 0.810 0.084
11 237 0.23 0.03 2.41 0.84 0.850 0.57
12 536 0.16 0.04 0.95 0.32 0.729 1.62
Mean 0.12 2.55 0.38




Based on an 8 t to 8 PM time interval (12 hours) whereas baseline PVcs/hr for entry into the study were determined
during an 8 st to 8 AM time interval (24 hours).
t Subjects 1 and 9 showed 100% vc suppression during the entire administration interval; estimated ECw values were
not included in calculation of mean values.
pvc, premature ventricular contraction; EC50, plasma drug concentration at 50% of E,,, (g/mL); ECw, plasma drug
concentration at 90% of E,,,. (pg/mL).
bles II and III). Spontaneous variability in PVCs,
which has been documented in other studies,3235
was reduced by averaging the effect-concentration
data over 4-hour intervals. Holazo et a136 showed that
6-hour averaged data sets adequately described the
antiarrhythmic effect profile for cibenzoline and im-
proved correlation compared with using hourly in-
tervals.
Individual antiarrhythmic response to plasma con-
centrations of pirmenol was highly variable, as
shown by the representative effect-concentration
plots in Figure 3. The overall effect-concentration
relationship (using mean EC50 and S values) with
individual data superimposed on the curve is shown
in Figure 5. This figure demonstrates that individual
data are reasonably well represented by the mean
parameter estimates.
The plasma concentration of pirmenol required for
EC90 was selected to represent the minimum effective
concentration as at least 70% to 80% reduction from
baseline of PVCs is generally accepted as the crite-
rion for antiarrhythmic drug efficacy.37 The mean
(±SD) EC90 value of 1.29 ± 0.66 g/mL (without pa-
tient no. 12) for total pirmenol was consistent with
the previously reported average minimum effective
concentration of approximately I j.vg/mL, which was
determined from observation of the pirmenol con-
centration corresponding to 70% to 90% reduction
in PVCs.146’7’3844 Minimum effective concentrations
for an individual patient ranged from 0.2 jg/mL to
2.75 ig/mL in these literature reports and are similar
to the estimated EC90 values of 0.40 tg/mL to 2.41
pg/mL in this study (except for patient no. 12 who
had an EC90 value of 11.3 g/mL). Mean (±SD) effec-
tive concentration of unbound pirmenol (EC90) in
this study was 0.25 ± 0.17 jg/mL (without patient
no. 12); values have not been reported for effective
concentration of unbound pirmenol in earlier stud-
ies.
Based on total drug, clearance of (-)-pirmenol is
20% higher than clearance of (+)-pirmenol, whereas
clearance based on unbound drug reveals a larger
difference (49%) between enantiomers. Both of
these differences were statistically significant.
Smaller difference in clearance based on total drug
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Figure 5. Total and unbound effect-concentration profiles of pir-
menol in patients with PVCs after the combined final 100-mg and
200-mg doses of repeated oral administration of racemic pir-
menol. The solid line represents the hypothetical effect-concen-
tration curve based on mean EC50 and S values as displayed in
Tables II and III. Individual data are superimposed on this curve.
Figure 4. Mean (± SE) effect-time profile after the final 100-mg or
200-mg doses of repeated administration of racemic pirmenol ev-
ery 12 hours to patients with PVCs. Data are plotted at the mid-
point of each 4-hour interval in which average PVC reduction was
calculated. Baseline values (PVCs per hour) used to calculate PVC
reduction in this figure were determined separately for day (8:00
AM to 8:00 PM) and night (8:00 PM to 8:00 AM) periods to prevent
bias in PVC reduction, which could occur if a subject had diurnal
variation in baseline PVCs.
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the more rapidly cleared unbound (-)-pirmenol is
also more extensively bound to plasma proteins than
is (+)-pirmenol. Pirmenol enantiomers are distrib-
uted to tissues to a similar extent.
Pharmacokinetics of pirmenol appear to be dose
proportional from 100 mg to 200 mg when total pir-
menol is measured. However, unbound pirmenol
shows a dose-dependent clearance with 20% slower
clearance at the higher dose for both enantiomers.
Because protein binding was saturable for most pa-
tients, f increased at the 200-mg dose (in the oppo-
site direction of unbound clearance), resulting in ap-
parent linearity of pharmacokinetics of total pir-
menol.
Antiarrhythmic effect can be correlated with
plasma concentrations of pirmenol using a sigmoid
Emac model. Patients show a large variability in their
antiarrhythmic response to plasma concentrations of
pirmenol (total or unbound). The median value for
EC90 of racemic pirmenol was approximately 1.5 tg/
mL.
Although unbound clearance of (-)-pirmenol was
significantly higher (42% to 49%) than its antipode,
0.2 0.4 0.6 0.8 1.0
Unbound Pirmenol Cone. (pg/mL)
the clinical significance of this difference (in terms
of dynamics) cannot be determined as it is uncertain
whether pirmenol enantiomers will have similar an-
tiarrhythmic activities in humans. In the absence of
regulatory agency approval for administration of in-
dividual enantiomer to humans, only the racemate
has been studied to date.
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